![]() |
General description
An authoritative survey of this fascinating strategy for drug discovery: using complementary oligonucleotides to block expression of disease-associated genes. Contributors discuss selection of gene targets, synthesis of oligonucleotides, routes of administration, and issues of pharmacokinetics. Current research on anti-viral drugs, cancer treatment, and therapies for genetic disorders is summarized.
Table of Contents
History of Antisense Oligonucleotides.
Pharmacology of Antisense Therapeutic Agents: Cancer and Inflammation. Antisense Efficacy: Site-Restricted In Vivo and Ex Vivo Models. Antisense Blockade of Expression: SNAP-25 In Vitro and In Vivo. Antisense Tumor Therapy: Activated C-Ha-ras Oncogene in the Mouse. Antisense Inhibition of Protein Synthesis and Function: Rabbit Retinal Protein. c-Myb in Smooth Muscle Cells. Antisense Therapy of Hepatitis B Virus Infection: In Vivo Analyses in the Duck Hepatitis B Virus Model. Antisense-Mediated Inhibition of Protein Synthesis: Rational Drug Design, Pharmacokinetics, Intracerebral Application, and Organ Uptake of Phosphorothioate Oligodeoxynucleotides. Antisense rel A in Cancer. Continuous Infusion of Antisense Phosphorothioate Therapeutics. Protein Kinase-A Directed Antisense Therapy of Tumor Growth In Vivo: The Antisense Effects Outlast Antisense Survival. Antisense Therapeutics in the Central Nervous System: The Induction of c-fos. Comparative Pharmacokinetics of Antisense Oligonucleotides. Index.
| ||||||||